Sign in or Register   Sign in or Register
  |  

Rabbit Anti-GPR119 Recombinant Antibody (EG1366) (CBMAB-EN1645-LY)

The product is antibody recognizes GPR119. The antibody EG1366 immunoassay techniques such as: WB: 1:500~1:1000 IF: 1:100~1:500 ELISA: 1:1000.
See all GPR119 antibodies

Summary

Host Animal
Rabbit
Specificity
Human
Clone
EG1366
Antibody Isotype
IgG
Application
WB: 1:500~1:1000 IF: 1:100~1:500 ELISA: 1:1000

Basic Information

Immunogen
The antibody was produced against synthesized peptide derived from internal of human GPR119.
Specificity
Human
Antibody Isotype
IgG
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
G Protein-Coupled Receptor 119
Introduction
This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010]
Entrez Gene ID
139760
UniProt ID
Q8TDV5
Alternative Names
G Protein-Coupled Receptor 119; Glucose-Dependent Insulinotropic Receptor; G-Protein Coupled Receptor 119; G-Protein Coupled Receptor 2; GPCR2;
Function
Receptor for the endogenous fatty-acid ethanolamide oleoylethanolamide (OEA) and lysophosphatidylcholine (LPC). Functions as a glucose-dependent insulinotropic receptor. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Seems to act through a G(s) mediated pathway.
Biological Process
Adenylate cyclase-activating G protein-coupled receptor signaling pathway Source: GO_Central
Regulation of metabolic process Source: GO_Central
Cellular Location
Cell membrane
Topology
Extracellular: 1-12
Helical: 13-33
Cytoplasmic: 34-37
Helical: 38-58
Extracellular: 59-81
Helical: 82-102
Cytoplasmic: 103-125
Helical: 126-146
Extracellular: 147-164
Helical: 165-185
Cytoplasmic: 186-226
Helical: 227-247
Extracellular: 248-262
Helical: 263-283
Cytoplasmic: 284-335

Qian, Y., Wang, J., Yang, L., Liu, Y., Wang, L., Liu, W., ... & Qiao, A. (2022). Activation and signaling mechanism revealed by GPR119-Gs complex structures. Nature Communications, 13(1), 7033.

Xu, P., Huang, S., Guo, S., Yun, Y., Cheng, X., He, X., ... & Xu, H. E. (2022). Structural identification of lysophosphatidylcholines as activating ligands for orphan receptor GPR119. Nature Structural & Molecular Biology, 29(9), 863-870.

Manaithiya, A., Alam, O., Sharma, V., Naim, M. J., Mittal, S., & Khan, I. A. (2021). GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus. Bioorganic Chemistry, 113, 104998.

Zhao, J., Zhao, Y., Hu, Y., & Peng, J. (2021). Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. Cellular & Molecular Biology Letters, 26(1), 1-28.

Im, D. S. (2021). GPR119 and GPR55 as receptors for fatty acid ethanolamides, oleoylethanolamide and palmitoylethanolamide. International journal of molecular sciences, 22(3), 1034.

Li, H., Fang, Y., Guo, S., & Yang, Z. (2021). GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present). Expert Opinion on Therapeutic Patents, 31(9), 795-808.

Higuchi, S., Ahmad, T. R., Argueta, D. A., Perez, P. A., Zhao, C., Schwartz, G. J., ... & Haeusler, R. A. (2020). Bile acid composition regulates GPR119-dependent intestinal lipid sensing and food intake regulation in mice. Gut, 69(9), 1620-1628.

Yamada, Y., Terauchi, Y., Watada, H., Nakatsuka, Y., Shiosakai, K., Washio, T., & Taguchi, T. (2018). Efficacy and safety of GPR119 agonist DS-8500a in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Advances in Therapy, 35, 367-381.

Li, N. X., Brown, S., Kowalski, T., Wu, M., Yang, L., Dai, G., ... & Kelley, D. E. (2018). GPR119 agonism increases glucagon secretion during insulin-induced hypoglycemia. Diabetes, 67(7), 1401-1413.

Yang, J. W., Kim, H. S., Choi, Y. W., Kim, Y. M., & Kang, K. W. (2018). Therapeutic application of GPR119 ligands in metabolic disorders. Diabetes, Obesity and Metabolism, 20(2), 257-269.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Rabbit Anti-GPR119 Recombinant Antibody (EG1366)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare